Third Phase: Synthego Expanding Cell, Gene Therapy Capabilities with $200M Financing

The Series E accounts for nearly half of the $450 million or more in total financing that Synthego has raised since it was founded in 2012 by Dabrowski and his brother Michael. In the decade since, Synthego has seen its products cited in about 1,000 peer-reviewed publications and grown its customer base to about 17,000 CRISPR researchers across 45 countries. Last October, Synthego attracted more than 12,000 CRISPR researchers who participated online in its second virtual World CRISPR Day . . .

The post Third Phase: Synthego Expanding Cell, Gene Therapy Capabilities with $200M Financing appeared first on GEN – Genetic Engineering and Biotechnology News.

Source